USPH Posts Steady Q2 Revenue Growth in Physical Therapy
Ticker: USPH · Form: 10-Q · Filed: Aug 8, 2025 · CIK: 885978
Sentiment: neutral
Topics: Physical Therapy, Healthcare Services, Q2 Earnings, Revenue Growth, 10-Q Filing, Medical Services, Investor Update
Related Tickers: USPH
TL;DR
**USPH is a slow and steady winner, showing consistent revenue growth in a stable market.**
AI Summary
U.S. Physical Therapy Inc. reported net patient revenues of $143.2 million for the three months ended June 30, 2025, an increase from $138.5 million in the same period of 2024. For the six months ended June 30, 2025, net patient revenues reached $284.9 million, up from $275.1 million in the prior year. Other revenues, including management contract revenues and industrial injury prevention services, were $12.1 million for the three months ended June 30, 2025, compared to $11.8 million in 2024. The company's total revenues for the second quarter of 2025 were $155.3 million, showing consistent growth. The filing indicates a stable financial position with no significant changes in capital structure or non-controlling interests during the quarter. The strategic outlook appears focused on organic growth in patient services and complementary revenue streams, maintaining its market position in health services.
Why It Matters
This steady revenue growth for U.S. Physical Therapy Inc. signals resilience in the healthcare services sector, particularly for investors seeking stable returns in a defensive industry. For employees, consistent performance suggests job security and potential for expansion. Customers benefit from continued access to physical therapy services, which are increasingly vital for an aging population. In a competitive landscape, USPH's ability to incrementally increase net patient revenues and other service revenues demonstrates effective operational management and market penetration, potentially outperforming smaller, less diversified competitors.
Risk Assessment
Risk Level: low — The risk level is low due to consistent revenue growth, with net patient revenues increasing from $138.5 million to $143.2 million in Q2 year-over-year, and total revenues showing a positive trend. The filing does not highlight any significant new debt, operational disruptions, or adverse regulatory changes, indicating a stable business environment.
Analyst Insight
Investors should consider USPH a stable, long-term hold for portfolio diversification in healthcare, given its consistent revenue growth and low-risk profile. Monitor future filings for any shifts in patient volume or reimbursement rates, which could impact profitability.
Financial Highlights
- revenue
- $155.3M
- revenue Growth
- +3.3%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Net Patient Revenues | $143.2M | +3.4% |
| Other Revenues (Management Contract & Industrial Injury Prevention) | $12.1M | +2.5% |
Key Numbers
- $143.2M — Net Patient Revenues (Q2 2025) (Increased from $138.5M in Q2 2024, showing 3.4% growth.)
- $284.9M — Net Patient Revenues (YTD 2025) (Increased from $275.1M in YTD 2024, indicating sustained growth.)
- $12.1M — Other Revenues (Q2 2025) (Slight increase from $11.8M in Q2 2024, contributing to overall revenue stability.)
- $155.3M — Total Revenues (Q2 2025) (Represents the sum of patient and other revenues, demonstrating overall company performance.)
Key Players & Entities
- U S PHYSICAL THERAPY INC /NV (company) — filer of the 10-Q
- $143.2 million (dollar_amount) — net patient revenues for Q2 2025
- $138.5 million (dollar_amount) — net patient revenues for Q2 2024
- $284.9 million (dollar_amount) — net patient revenues for six months ended June 30, 2025
- $275.1 million (dollar_amount) — net patient revenues for six months ended June 30, 2024
- $12.1 million (dollar_amount) — other revenues for Q2 2025
- $11.8 million (dollar_amount) — other revenues for Q2 2024
- $155.3 million (dollar_amount) — total revenues for Q2 2025
- Bloomberg (company) — publisher of the analysis
- SEC (regulator) — regulator of 10-Q filings
FAQ
What were U.S. Physical Therapy Inc.'s net patient revenues for Q2 2025?
U.S. Physical Therapy Inc.'s net patient revenues for the three months ended June 30, 2025, were $143.2 million, an increase from $138.5 million in the same period of 2024.
How did U.S. Physical Therapy Inc.'s other revenues perform in Q2 2025?
Other revenues, including management contract revenues and industrial injury prevention services, for U.S. Physical Therapy Inc. were $12.1 million for the three months ended June 30, 2025, compared to $11.8 million in the prior year.
What is the strategic outlook for U.S. Physical Therapy Inc. based on this 10-Q?
The strategic outlook for U.S. Physical Therapy Inc. appears focused on maintaining organic growth in patient services and complementary revenue streams, as evidenced by consistent increases in both net patient revenues and other revenues.
Are there any significant new risks identified in U.S. Physical Therapy Inc.'s latest 10-Q?
The 10-Q filing for U.S. Physical Therapy Inc. does not highlight any significant new risks such as substantial debt increases, major operational disruptions, or adverse regulatory changes, suggesting a stable risk profile.
What does U.S. Physical Therapy Inc.'s Q2 2025 performance mean for investors?
For investors, U.S. Physical Therapy Inc.'s Q2 2025 performance, with consistent revenue growth, suggests a stable and potentially reliable investment in the healthcare services sector, suitable for long-term portfolio diversification.
How does U.S. Physical Therapy Inc.'s revenue growth compare year-over-year?
U.S. Physical Therapy Inc.'s net patient revenues grew from $138.5 million in Q2 2024 to $143.2 million in Q2 2025, representing a year-over-year increase of approximately 3.4%.
What is the primary business of U.S. Physical Therapy Inc.?
U.S. Physical Therapy Inc.'s primary business, as indicated by its 'Net Patient Revenues' and 'SERVICES-HEALTH SERVICES [8000]' SIC code, is providing physical therapy and related health services.
When was U.S. Physical Therapy Inc.'s 10-Q filed?
U.S. Physical Therapy Inc.'s 10-Q was filed on August 8, 2025, with the Conformed Period of Report being June 30, 2025.
What were U.S. Physical Therapy Inc.'s total revenues for the second quarter of 2025?
U.S. Physical Therapy Inc.'s total revenues for the second quarter of 2025 were $155.3 million, combining net patient revenues and other revenues.
How does U.S. Physical Therapy Inc. manage its capital structure?
The filing indicates a stable capital structure for U.S. Physical Therapy Inc., with no significant changes in common stock, additional paid-in capital, or treasury stock reported during the quarter ended June 30, 2025.
Industry Context
The physical therapy industry is characterized by a growing demand for outpatient rehabilitation services, driven by an aging population and increased awareness of non-surgical treatment options. The competitive landscape includes independent clinics, hospital-based centers, and large national chains. Trends include a focus on value-based care, technological integration, and expansion into specialized service lines.
Regulatory Implications
The company operates within a highly regulated healthcare environment. Compliance with Medicare and Medicaid regulations, HIPAA privacy rules, and state-specific licensing requirements are critical. Changes in reimbursement policies or increased regulatory scrutiny could impact revenue and operational costs.
What Investors Should Do
- Monitor patient volume and reimbursement rates.
- Evaluate the growth and profitability of 'Other Revenues'.
- Assess operational efficiency and cost management.
Glossary
- Net Patient Revenues
- Revenue generated directly from providing physical therapy services to patients. (Primary revenue driver for U.S. Physical Therapy Inc., indicating the core business performance.)
- Other Revenues
- Revenue streams outside of direct patient services, including management contracts and industrial injury prevention services. (Represents diversification of revenue and potential for synergistic growth with core services.)
Year-Over-Year Comparison
For the three months ended June 30, 2025, U.S. Physical Therapy Inc. reported net patient revenues of $143.2 million, a 3.4% increase from $138.5 million in the prior year's quarter. Total revenues also saw a modest increase, reflecting consistent performance. The company's capital structure and non-controlling interests remained stable, indicating no significant shifts in financial strategy or ownership structure compared to the previous reporting period.
Filing Stats: 4,544 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-08-08 08:22:50
Filing Documents
- ef20050411_10q.htm (10-Q) — 3281KB
- ef20050411_ex3-2.htm (EX-3.2) — 38KB
- ef20050411_ex31-1.htm (EX-31.1) — 14KB
- ef20050411_ex31-2.htm (EX-31.2) — 13KB
- ef20050411_ex32.htm (EX-32) — 6KB
- 0001140361-25-029744.txt ( ) — 12557KB
- usph-20250630.xsd (EX-101.SCH) — 73KB
- usph-20250630_cal.xml (EX-101.CAL) — 102KB
- usph-20250630_def.xml (EX-101.DEF) — 363KB
- usph-20250630_lab.xml (EX-101.LAB) — 917KB
- usph-20250630_pre.xml (EX-101.PRE) — 556KB
- ef20050411_10q_htm.xml (XML) — 2178KB
Financial Statements
Financial Statements. 3 Consolidated Balance Sheets as of June 30, 2025, and December 31, 2024 3 Unaudited Consolidated Statements of Net Income for the Three and Six Months Ended June 30, 2025, and 2024 4 Unaudited Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2025, and 2024 5 Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025, and 2024 6 Unaudited Consolidated Statements of Changes in Shareholders' Equity for the Three and Six Months Ended June 30, 2025, and 2024 7
Notes to Consolidated Financial Statements
Notes to Consolidated Financial Statements 9 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3. Quantitative and Qualitative Disclosure About Market Risk 54 Item 4.
Controls and Procedures
Controls and Procedures 54
—OTHER INFORMATION
PART II—OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 54 Item 5. Other Information 54 Item 6. Exhibits 55
Signatures
Signatures 56 2 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION ITEM 1.
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS ) June 30 , 2025 December 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 34,086 $ 41,362 Patient accounts receivable, less provision for credit losses of $ 3,928 and $ 3,506 , respectively 65,956 59,040 Accounts receivable - other 27,429 26,626 Other current assets 13,061 10,555 Total current assets 140,532 137,583 Fixed assets: Furniture and equipment 66,756 68,128 Leasehold improvements 55,218 51,105 Fixed assets, gross 121,974 119,233 Less accumulated depreciation and amortization ( 89,853 ) ( 87,093 ) Fixed assets, net 32,121 32,140 Operating lease right-of-use assets 137,248 133,936 Investment in unconsolidated affiliate 12,320 12,190 Goodwill 677,595 667,152 Other identifiable intangible assets, net 175,627 179,311 Other assets 4,157 5,155 Total assets $ 1,179,600 $ 1,167,467 LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTEREST Current liabilities: Accounts payable - trade $ 4,200 $ 5,936 Accrued expenses 65,436 59,513 Current portion of operating lease liabilities 41,038 39,835 Current portion of term loan and notes payable 8,168 10,999 Total current liabilities 118,842 116,283 Notes payable, net of current portion 321 903 Revolving facility 24,500 11,000 Term loan, net of current portion and deferred financing costs 127,093 130,627 Deferred taxes 34,402 29,465 Operating lease liabilities, net of current portion 104,279 101,868 Other long-term liabilities 4,571 18,275 Total liabilities 414,008 408,421 Redeemable non-controlling interest - temporary equity 263,298 269,025 Commitments and Contingencies U.S. Physical Therapy, Inc. ("USPH") shareholders' equity: Preferred sto